24. V. I. Kaledin et al., JNCI
66 (5), 881–887 (1981).
25. C. Oussoren and G. Storm, Adv. Drug Deliv. Rev.
50, 143–156 (2001).
26. A. Supersaxo, W. R. Hein, and H. Steffen, Pharm. Res.
7 (2), 167–169 (1990).
27.. A. J. Harvey et al., Pharm. Res. (2010),
http://www.springerlink.com/content/j227p875h614x3w4/, accessed Oct. 13, 2010.
28 J. Gupta, E. I. Felner, and M. R. Prausnitz, Diabetes Technol. Ther.
11 (6), 329–337 (2009).
29. F. Cosman et al., J. Clin. Endocrinol. Metab.,
95, 151–158, (2010).
30. C. A. Frolik et al., Bone
33, 372–379 (2003).
31. L. A. Denson, Expert Opin. Drug Metab. Toxicol.
4 (12), 1569–1580 (2008).
32. T. Karpanen, and K. Alitalo, Journal of Experimental Medicine 194(6), F37–F42 (2001).
33. Y. Xie, T. R. Bagby, M. S. Cohen, and M. L. Forest, Expert Opinion on Drug Delivery 6(8), 785–792 (2009).
34. L. T. Kuhn, P. L. Pieto, and B. Wen, Cancer Research
69, 2135 (2009).
35. A. Arora, M. R. Prausnitz, and S. Mitagotri, Intern. Jrnl. of Pharmaceut.
364, 227–236 (2008)
36. S. A. Frech et al., The Lancet
341, 2019–2025 (2008).
37. G. M. Glenn et al., Vaccines
6 (5), 809–819 (2007).
38. S. Garg et al., Clin. Vaccine Immunol.
14( 7), 926-928 (2007).
39. A. C. Sintov et al., Jrnl. Control. Rel.
89 (2), 311–320 (2003).
40. M. M. Badran, J. Kuntsche, and A. Fahr, Eur. J. Pharm. Sci.
36 (4–5), 511–523 (2009).
|
